71°

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Readers' Choice

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

41.87 +0.08 (+0.18%)

Delayed Quote Updated: 2:21 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

43 44 Next >

Why Shares of Innate Pharma Jumped Thursday ↗

June 08, 2023

The company's collaboration agreement with Sanofi could soon pay off.

Via The Motley Fool

The 7 Most Reliable Dividend Stocks to Buy Now ↗

June 06, 2023

Faced with a tricky market backdrop, investors may take significant comfort with the most reliable dividend stocks to buy.

Via InvestorPlace

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Was This $3 Billion Deal a Wise Move for Sanofi? ↗

May 31, 2023

The French drugmaker appears to have meaningfully improved its portfolio with the acquisition.

Via The Motley Fool

3 Biotech Stocks to Avoid Like the Plague ↗

May 23, 2023

Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs.

Via InvestorPlace

Peering Into Sanofi's Recent Short Interest ↗

May 15, 2023

Via Benzinga

Sanofi (SNY) Q1 2023 Earnings Call Transcript ↗

April 28, 2023

SNY earnings call for the period ending March 31, 2023.

Via The Motley Fool

Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning

April 26, 2023

Via Investor Brand Network

Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained ↗

May 22, 2023

Via Benzinga

2 Bear Market Defying Stocks to Buy in May ↗

May 22, 2023

These stocks still have plenty of market-beating years ahead.

Via The Motley Fool

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

May 18, 2023

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

Via MarketBeat

Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗

May 17, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)

Via Benzinga

Rebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing ↗

May 12, 2023

CEOs of Eli Lilly And Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and PBM e

Via Benzinga

Earnings Outlook For Sanofi ↗

April 26, 2023

Via Benzinga

Sanofi (NASDAQ: SNY) Sets New 52-Week High in Tuesday Session

April 25, 2023

Via Investor Brand Network

Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody ↗

May 12, 2023

The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have

Via Benzinga

Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns ↗

May 12, 2023

The monoclonal antibody shot significantly reduced the risk of hospitalization in babies.

Via Investor's Business Daily

What Wall Street Is Saying About Disney Ahead Of Earnings ↗

May 10, 2023

Disney set to report amid fights with writers and DeSantis.

Via Talk Markets

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics ↗

May 10, 2023

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult

Via Benzinga

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

May 05, 2023

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

Via MarketBeat

7 Blue-Chip Stocks to Buy in May 2023 ↗

May 04, 2023

While not the most exciting sector available, rising fears in the market incentivizes the best blue-chip stocks to buy.

Via InvestorPlace

Why Regeneron Pharmaceuticals Shares Are Trading Lower Today ↗

May 04, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating

Via Benzinga

7 Stock Upgrades and Downgrades Alerts You Cannot Ignore ↗

May 04, 2023

Analyst stock upgrades and downgrades caught the market's attention in the last week and putting investors on notice for buys and sells.

Via InvestorPlace

First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories ↗

May 01, 2023

Benzinga

Via Benzinga

European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals ↗

May 01, 2023

The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public...

Via Benzinga

Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront ↗

May 01, 2023

Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA (NASDAQ: SNY) for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently...

Via Benzinga

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗

April 28, 2023

Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.

Via Investor's Business Daily

Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales ↗

April 27, 2023

French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in

Via Benzinga

Earnings Scheduled For April 27, 2023 ↗

April 27, 2023

Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter.

Via Benzinga

US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet' ↗

April 27, 2023

Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher.

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

43 44 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Sanofi - American Depositary Shares (NQ:SNY)

All News about Sanofi - American Depositary Shares

Sections

Services